Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L

Journal of Clinical Oncology

Volumn 34, Issue 27, 2016, Pages 3248-3257

  Urata, Yoshiko ^a   Katakami, Nobuyuki ^b   Morita, Satoshi ^d   Kaji, Reiko ^b   Yoshioka, Hiroshige ^e   Seto, Takashi ^f   Satouchi, Miyako ^a   Iwamoto, Yasuo ^h   Kanehara, Masashi ^h   Fujimoto, Daichi ^c   Ikeda, Norihiko ⁱ   Murakami, Haruyasu ^j   Daga, Haruko ^k   Oguri, Tetsuya ^o   Goto, Isao ^m   Imamura, Fumio ^l   Sugawara, Shunichi ^p   Saka, Hideo ⁿ   Nogami, Naoyuki ^q   Negoro, Shunichi ^a   Nakagawa, Kazuhiko ^r   Nakanishi, Yoichi ^g   more..

^a HYOGO CANCER CENTER   (Japan)

^b INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^c KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^d KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e KURASHIKI CENTRAL HOSPITAL   (Japan)

^f NATIONAL KYUSHU CANCER CENTER   (Japan)

^g KYUSHU UNIVERSITY   (Japan)

^h HIROSHIMA CITY HOSPITAL   (Japan)

ⁱ TOKYO MEDICAL UNIVERSITY   (Japan)

^j SHIZUOKA CANCER CENTER   (Japan)

^k OSAKA CITY GENERAL HOSPITAL   (Japan)

^l OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^m OSAKA MEDICAL COLLEGE   (Japan)

ⁿ NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^o NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^p SENDAI KOUSEI HOSPITAL   (Japan)

^q NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^r KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HUMAN; INFECTION; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PARONYCHIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SKIN TOXICITY; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; ENZYMOLOGY; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; PATHOLOGY;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; ERLOTINIB HYDROCHLORIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84989913195     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.4154     Document Type: Article

References (16)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63:11-30, 2013
2. Travis WD, Brambilla E, Noguchi M, et al: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:244-285, 2011
3. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial). J Clin Oncol 21:2237-2246, 2003
4. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290:2149-2158, 2003
5. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
6. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004
7. Thatcher N, Chang A, Parikh P, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537, 2005
8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al; Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
9. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380-2388, 2010
10. Mitsudomi T, Morita S, Yatabe Y, et al; Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 11:121-128, 2010
11. Satoh H, Inoue A, Kobayashi K, et al: Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations. J Thorac Oncol 6:1413-1417, 2011
12. Hagiwara K, Kobayashi K: Importance of the cytological sampled for the epidermal growth factor receptor gene mutation for non-small cell lung cancer. Cancer Sci 104:291-297, 2013
13. Rosell R, Moran T, Queralt C, et al; Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958-967, 2009
14. Zhou C, Wu YL, Chen G, et al: Erlotinib versus chemotherapyas first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735-742, 2011
15. Rosell R, Carcereny E, Gervais R, et al; Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239-246, 2012
16. Yang JC, Wu YL, Schuler M, et al: Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 16:141-151, 2015